knowledge -WSS

knowledge

author：explore 2025-08-12 05:30:42 - browse：7644

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： When women are denied an abortion, their children fare worse than peers

entertainment

WSS

AI can decode, harness the power of the humane immune system

Chemotherapy drug shortage eases slightly but still widespread

When women are denied an abortion, their children fare worse than peers

Morgan Health, with ambitious aims, wants you to know it’s still here

Stroke deaths set to near 10 million globally by 2050

Histogen: Failed biotech offers rare public look inside

explore

knowledge

knowledge

Anesthesiologist group: stop taking Ozempic before surgery

Bristol 'take

George Santos makes 1st court appearance after pleading not guilty to 13 counts

When women are denied an abortion, their children fare worse than peers

Medical records are filled with copy

Feng Zhang, Grail founder join forces on new gene editing startup

Malaria cases in Florida and Texas: Here’s what you need to know

3 medical device trends to watch in 2024

What does generative AI mean for health care? We asked experts

White House finalizes ITC's import ban of latest Apple Watches

leisure time

Feng Zhang, Grail founder join forces on new gene editing startup

The future of health care in the House

Federal weight loss drug coverage is 30 years out of date

Analysis of telehealth claims data suggest service duplication

Bill would stop addiction treatment from triggering child abuse inquiry

FDA authorizes Novavax’s updated Covid

focus

explore

entertainment

leisure time